Revvity, Inc. (NYSE:RVTY – Get Free Report) has been assigned an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $118.91.
Several equities analysts have issued reports on the company. Stifel Nicolaus boosted their price target on Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a research note on Friday, February 2nd. KeyCorp increased their target price on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. Raymond James lifted their price target on shares of Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Evercore ISI raised shares of Revvity from an “in-line” rating to an “outperform” rating and increased their price objective for the stock from $88.00 to $125.00 in a research report on Thursday, January 4th. Finally, UBS Group lowered Revvity from a “buy” rating to a “neutral” rating and boosted their target price for the company from $105.00 to $125.00 in a research report on Tuesday, January 16th.
Get Our Latest Stock Analysis on RVTY
Insider Buying and Selling at Revvity
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of Revvity by 3.3% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 317,292 shares of the company’s stock worth $33,316,000 after purchasing an additional 10,198 shares during the last quarter. Oak Thistle LLC bought a new position in Revvity during the first quarter valued at $607,000. Artemis Investment Management LLP grew its holdings in Revvity by 80.5% during the first quarter. Artemis Investment Management LLP now owns 88,718 shares of the company’s stock valued at $9,311,000 after purchasing an additional 39,573 shares during the period. RDA Financial Network purchased a new stake in Revvity in the first quarter worth $322,000. Finally, Gulf International Bank UK Ltd raised its stake in shares of Revvity by 3.8% in the first quarter. Gulf International Bank UK Ltd now owns 10,795 shares of the company’s stock valued at $1,133,000 after buying an additional 400 shares during the period. Institutional investors own 86.65% of the company’s stock.
Revvity Trading Up 1.5 %
RVTY opened at $100.86 on Monday. The stock has a market cap of $12.46 billion, a PE ratio of 18.34, a price-to-earnings-growth ratio of 2.62 and a beta of 1.09. The company has a quick ratio of 1.77, a current ratio of 2.07 and a debt-to-equity ratio of 0.40. Revvity has a twelve month low of $79.50 and a twelve month high of $135.67. The company has a fifty day moving average of $104.78 and a 200-day moving average of $101.64.
Revvity (NYSE:RVTY – Get Free Report) last issued its quarterly earnings results on Thursday, February 1st. The company reported $1.25 earnings per share for the quarter, topping analysts’ consensus estimates of $1.15 by $0.10. The firm had revenue of $695.90 million during the quarter. Revvity had a return on equity of 7.41% and a net margin of 25.20%. On average, sell-side analysts predict that Revvity will post 4.65 EPS for the current year.
Revvity Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Friday, April 19th will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date is Thursday, April 18th. Revvity’s payout ratio is currently 5.09%.
Revvity Company Profile
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Featured Articles
- Five stocks we like better than Revvity
- Earnings Per Share Calculator: How to Calculate EPS
- Comprehensive Analysis of PayPal Stock
- What is the NASDAQ Stock Exchange?
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- Canadian Penny Stocks: Can They Make You Rich?
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.